Coverage by Oliver Longstaff for Pα+, edited by Josh Hardman. Last month, we learned that the Psychopharmacologic Drugs Advisory Committee (PDAC), convened by the FDA to advise on the potential approval of MDMA-assisted therapy to treat patients with PTSD, had delivered a negative verdict: 10-1 against the notion that the therapeutic benefits outweigh the risks involved.
